- Home
- DSP vs AQST Comparison
DSP vs AQST Comparison
Compare DSP & AQST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | DSP | AQST |
|---|---|---|
| Founded | 1999 | 2004 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 184.3M | 809.3M |
| IPO Year | 2021 | 2018 |
Fundamental Metrics
Financial Performance| Metric | DSP | AQST |
|---|---|---|
| Price | $11.61 | $6.27 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 8 | 7 |
| Target Price | ★ $18.50 | $10.00 |
| AVG Volume (30 Days) | 234.0K | ★ 2.4M |
| Earning Date | 11-10-2025 | 11-05-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 29.49 | N/A |
| EPS | ★ 0.10 | N/A |
| Revenue | ★ $324,131,000.00 | $43,397,000.00 |
| Revenue This Year | $17.79 | N/A |
| Revenue Next Year | $17.72 | $52.69 |
| P/E Ratio | $118.61 | ★ N/A |
| Revenue Growth | ★ 22.97 | N/A |
| 52 Week Low | $8.11 | $2.12 |
| 52 Week High | $26.33 | $7.55 |
Technical Indicators
Market Signals| Indicator | DSP | AQST |
|---|---|---|
| Relative Strength Index (RSI) | 64.12 | 52.76 |
| Support Level | $11.07 | $5.99 |
| Resistance Level | $12.48 | $6.44 |
| Average True Range (ATR) | 0.49 | 0.32 |
| MACD | 0.07 | 0.03 |
| Stochastic Oscillator | 68.67 | 54.73 |
Price Performance
Historical ComparisonAbout DSP Viant Technology Inc.
Viant Technology Inc is an advertising software company. The software enables the programmatic purchase of advertising, which is the electronification of the advertising buying process. It operates a cloud-based demand side platform ("DSP") that is used by marketers and its advertising agencies to centralize the planning, buying and measurement of its advertising across channels, including connected TV (CTV), streaming audio, digital out-of-home, mobile and desktop.
About AQST Aquestive Therapeutics Inc.
Aquestive Therapeutics Inc is a specialty pharmaceutical company engaged in developing and commercializing differentiated products to meet medical needs. Its later-stage product pipeline focuses on the treatment of diseases of the Central Nervous System (CNS), and an earlier-stage pipeline for the treatment of severe allergic reactions, including anaphylaxis. Its commercial product portfolio includes Suboxone, Emylif, Ondif and Sympazan. The product pipeline includes Libervant Buccal Film, AQST-108. The majority of its revenue comes from the United States.